^
    Back
    Association details:
    Biomarker:AKT1 mutation
    Cancer:Endometrial Cancer
    Drug:Torisel (temsirolimus) (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Gynecol Oncol
    Title:

    Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study

    Excerpt:
    AKT1 mutations were associated with a higher rate of response and longer PFS.
    DOI:
    10.1016/j.ygyno.2016.02.025